We are counted amongst as the foremost organizations, engaged in offering Tropicamide. This drug helps in lowering hepatic cholesterol synthesis by competitively inhibiting HMG-CoA reductase. It provides the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Tropicamide decreases serum LDL cholesterol by 29-32%, increases high density lipoprotein (HDL) cholesterol by 4.6-7.3%, and decrease triglyceride levels by 2-12%. It is a potent anticholesteremic agent, inhibits 3-hydroxy-3-methylglutaryl coenzyme. It also stimulates the production of low-density lipoprotein receptors in the liver.